Description

Watch VENN session 3 “Monitoring”.
In the third recorded session from the V.E.NN virtual meeting, listen to our expert faculty discussing best practices in Europe for the follow-up and monitoring of patients who have received vosoritide therapy. Topics include how patient monitoring affects time management and resources in the clinic, and how to keep the patients motivated throughout treatment. Our experts also review and discuss cases from their own clinics, and answer questions from the audience regarding patient monitoring.

The total viewing time for this session is approximately 1 hour 12 minutes. To view individual talks from within the Assessment session, please refer to the following timings:
• Overview, objectives, agenda and disclosures 00:00:00 to 00:01:50
• Follow-up and monitoring (Geneviève Baujat) 00:01:51 to 00:15:58
• Emerging capacity requirements (Tilman Rohrer) 00:15:59 to 00:26:40
• Keeping motivation (and adherence) high (Kerstin Schütz) 00:26:41 to 00:36:05
• Case study: Monitoring (Ekkehart Lausch) 00:36:06 to 00:54:49
• Panel discussion/Q&A and closing remarks 00:54:50 to 01:11:57

This video is for viewing by healthcare professionals only.

VOXZOGO®▼ (vosoritide) is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing. If you would like to view the current abbreviated prescribing information, please visit https://www.achondroplasia.expert/prescribing-information.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported to drugsafety@bmrn.com.
For general questions about BioMarin disease areas or products, contact medinfoeu@bmrn.com.

Date of preparation: November 2022; EU-VOX-00741